Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters

Cancer Research

Volumn 58, Issue 22, 1998, Pages 5137-5143

  Chu, Xiao Yan ^a   Kato, Yukio ^a   Ueda, Kaoru ^a   Suzuki, Hiroshi ^a   Niinuma, Kayoko ^a   Tyson, Charles A ^b   Weizer, Valorie ^b   Dabbs, Jack E ^b   Froehlich, Ritchie ^b   Green, Carol E ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN;

ACTIVE TRANSPORT; ADULT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG BILE LEVEL; DRUG DISPOSITION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; INTRAHEPATIC BILE DUCT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE; BILE CANALICULI; CAMPTOTHECIN; HUMANS; LEUKOTRIENE C4; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032533498     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Andoh, T., Ishii, K., and Suzuki, Y. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA, 84: 5565-5569, 1987.
2. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989.
3. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
4. Kojima, A., Shinkai, T., and Saijo, N. Cytogenetic effects of CPT-11 and its active metabolite, SN-38, on human lymphocytes. Jpn. J. Clin. Oncol., 23: 116-122, 1993.
5. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
6. Kaneda, N., and Yokokura, T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res., 50: 1721-1725, 1990.
7. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
8. Atsumi, R., Suzuki, W., and Hakusui, H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica, 21: 1159-1169, 1991.
9. Rivory, L. P., Riou, J-F., Haaz, M-C., Sable, S., Vuilhorgne, M., Commercon, A., Pond, S. M., and Robert, J. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res., 56: 3689-3694, 1996.
10. Hazz, M-C., Rivory, L., Riche, C., Vernillet, L., and Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsome: participation of cytochrome P-450 3A and drug interactions. Cancer Res., 58: 468-472, 1998.
11. Gandia, D., Armand, J., Chabot, G., Abigerges, D., Rougier, P., Ruffile, P., Cote, C., and Mathieu-Boue, A. Phase I study of the new camptothecin analogue CPT-11 administered every 3 weeks. Proc. Am. Assoc. Cancer Res., 33: 260, 1992.
12. Kudoh, S., Fukuoka, M., Masuda, N., Yoshikawa, A., Kusunoki, Y., Matsui, K., Negoro, S-I., Takifugi, N., Nakagawa, K., Hirashima, T., Yana, T., and Takada, M. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn. J. Cancer Res., 86: 406-413, 1995.
13. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84: 697-702, 1993.
14. Narita, M., Nagai, E., Hagiwara, H., Aburada, M., Yokoi, T., and Kamataki, T. Inhibition of β-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica, 23: 5-10, 1993.
15. Takasuna, K., Kasai, Y., Kitano, Y., Mori, K., Kobayashi, R., Hagiwara, T., Kakihata, K., Hirohashi, M., Nomura, M., Nagai, E., and Kamataki, T. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res., 86: 978-984, 1995.
16. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
17. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., and Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest., 101: 847-854, 1998.
18. Chu, X-Y., Kato, Y., Niinuma, K., Sudo, K., Hakusui, H., and Sugiyama, Y. Multispecific organic anion transporter (cMOAT) is responsible for biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther., 281: 304-314, 1997.
19. Chu, X-Y., Kato, Y., and Sugiyama, Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res., 57: 1934-1938, 1997.
20. Gandia, D., Armand, J., Chabot, G., Abigerges, D., Rougier, P., Ruffile, P., Cote, C., and Mathieu-Boue, A. Phase I study of the new camptothecin analogue CPT-11 administered every 3 weeks. Proc. Am. Assoc. Cancer Res., 33: 260, 1992.
21. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T. L., Rock, M. K., and Donehower, R. C. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-min infusion every 3 weeks. Cancer Res., 54: 427-436, 1994.
22. Sasaki, Y., Hakusui, H., Mizuno, S., Morita, M., Miya, T., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., and Saijo, N. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn. J. Cancer Res., 86: 101-110, 1995.
23. de Forni, M., Bugat, R., Chabot, G. G., Culine, S., Extra, J-M., Gouyette, A., Madelaine, I., Marty, M. E., and Mathieu-Boue, A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res., 54: 4347-4354, 1994.
24. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M., Extra, J. M., Mahjoubi, M., Herait, P., Armand, J. P., and Bugat, R. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol., 6: 141-151, 1995.
25. Rothenberg, M. L., Kuhn, J. G., Burris, H. A. III, Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., Rodriguez, G. I., Rock, M. K., and VonHoff, D. D. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11: 2194-2204, 1993.
26. Lokiec, F., Canal, P., Gay, C., Chatelut, E., Armand, J. P., Roche, H., Bugat, R., Goncalves, E., and Mathieu-Boue, A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol., 36: 79-82, 1995.
27. Kamimoto, Y., Gatmaitan, Z., Hsu, J., and Arias, I. M. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J. Biol. Chem., 264: 11693-11698, 1989.
28. Meier, P. J., Sztul, E. S., Reuben, A., and Boyer, J. L. Mechanisms of taurocholate transport in canalicular and basolateral rat liver plasma membrane vesicles. J. Cell Biol., 98: 991-1000, 1984.
29. Adachi, Y., Kobayashi, H., Kurumi, Y., Shouji, M., Kitano, M., and Yamamoto, T. ATP-dependent taurocholate transport by rat liver canalicular membrane vesicles. Hepatology, 14: 655-659, 1991.
30. Ishikawa, T., Müller, M., Klünemann, C., Schaub, T., and Keppler, D. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. J. Biol. Chem., 265: 19279-19286, 1990.
31. Akerboom, T. P. M., Narayanaswami, V., Kunst, M., and Sies, H. ATP-dependent S-(2,4-dinitrophenyl) glutathione transport in canalicular plasma membrane vesicles from rat liver. J. Biol. Chem., 266: 13147-13152, 1991.
32. Paulusma, C. C., Bosma, P. J., Zaman, G. J. R., Bakker, C. T. M., Otter, M., Scheffer, G. L., Scheper, R. J., Borst, P., and Elferink, R. P. J. O. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Washington DC), 277: 1126-1128, 1996.
33. Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T., and Sugiyama, Y. Molecular cloning of canalicular multispecific organic anion transporter (cMOAT) whose expression is defective in mutant rats with hereditary conjugated hyperbilirubinemia (EHBR). Am. J. Physiol., 272: G16-G22, 1997.
34. Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., Van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., Van der Lugt, N. M. T., van Roon, M. A., van der Valk, M. A., Offerhaus, G. J. A., Berns, A. J. M., and Borst, P. Homozygous disruption of the murine mdr2 p-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell, 75: 451-462, 1993.
35. Cole, S. P. C., Bhardwaj, J., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
36. Jedlitschky, G., Leier, I., Buchholz, U., Center, M., and Keppler, D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res., 54: 4833-4836, 1994.
37. Mayer, R., Kartenbeck, J., Buchler, M., Jedlitschky, G., Leier, I., and Keppler, D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J. Cell Biol., 131: 137-150, 1995.
38. 4 and structurally related conjugates. J. Biol. Chem., 269: 27807-27810, 1994.
39. Jedlitschky, G., Leier, I., Buchholz, U., Barnouin, K., Kurz, G., and Keppler, D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res., 56: 988-994, 1996.
40. Loe, D. W., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. ATP-dependent 17β-estradiol 17-(β-D-glucuronide) transport by multidrug resistance protein (MRP). J. Biol. Chem., 271: 9683-9689, 1996.
41. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S., and Kuwano, M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res., 56: 4124-4129, 1996.
42. Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., Eijk, M. J. T., and Juijn, J. A. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRPI), in human cancer cell lines. Cancer Res., 57: 3537-3547, 1997.
43. Paulusma, C. C., and Elferink, R. P. J. O. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J. Mol. Med., 75: 420-428, 1997.
44. Paulusma, C. C., Kool, M., Bosma, P. J., Scheffer, G. L., Borg, F., Scheper, R. J., Tytgat, G. N. J., Borst, P., Baas, F., and Elferink, R. P. J. O. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology, 25: 1539-1542, 1997.
45. Kobayashi, K., Sogame, Y., Hara, H., and Hayashi, K. Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. J. Biol. Chem., 265: 7737-7741, 1990.
46. Inoue, M., Akerboom, T. P. M., Sies, H., Kinne, R., Thao, T., and Arias, I. M. Biliary transport of glutathione S-conjugate by rat liver canalicular membrane vesicles. J. Biol. Chem., 259: 4998-5002, 1984.
47. Yamazaki, M., Suzuki, H., and Sugiyama, Y. Recent advances in carrier mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res., 13: 497-513, 1996.
48. Wolters, H., Spiering, M., Gerding, A., Slooff, M. J. H., Kuipers, F., Hardonk, M. J., and Vonk, R. J. Isolation and characterization of canalicular and basolateral plasma membrane fractions from human liver. Biochim. Biophys. Acta. 1069: 61-69, 1991.
49. Wolters, H., Kuipers, F., Slooff, M. J. H., and Vonk, R. J. Adenosine triphosphate-dependent taurocholate transport in human liver plasma membranes. J. Clin. Invest., 90: 2321-2326, 1992.
50. Bradford, M. M. A rapid and sensitive method for the quantitation of microsomal quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
51. Yamaoka, K., Tanigawara, Y., Nakagawa, T., and Uno, T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiol-Dyn., 4: 879-885, 1981.
52. Yamaoka, K., Nakagawa, T., and Uno, T. Application of Akaike's Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165-175, 1978.
53. Sasaki, Y., Yoshida, Y., Sudoh, K., Hakusui, H., Fujii, H., Ohtsu, T., Wakita, H., Igarashi, T., and Itoh, K. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn. J. Cancer Res., 86: 111-116, 1995.